Quick Comparison
| Crystagen | Livagen | |
|---|---|---|
| Half-Life | Approximately 30 minutes (acute pharmacology); proposed gene-expression effects outlast plasma exposure | Approximately 30 minutes (acute pharmacology); proposed gene-expression effects outlast plasma exposure |
| Typical Dosage | Oral (capsule): 100-200 mg once daily for 10-30 day cycles, repeated 2-3 times per year. Subcutaneous injection: 1-5 mg per dose, alternate days for 10-20 day cycles. Standard Khavinson cycling protocol. | Oral (capsule): 100-200 mg once daily for 10-30 day cycles, repeated 2-3 times per year. Subcutaneous injection: 1-5 mg per dose, alternate days for 10-20 day cycles. Standard Khavinson cycling rather than continuous use. |
| Administration | Oral capsule or subcutaneous injection (cycled) | Oral capsule or subcutaneous injection (cycled) |
| Research Papers | 1 papers | 5 papers |
| Categories |
Mechanism of Action
Crystagen
Crystagen is a short Khavinson tripeptide (Glu-Asp-Pro) positioned as the immune and thymus-targeted bioregulator within the wider Khavinson peptide family. The proposed mechanism follows the standard family framework: short peptides interact with gene promoter sequences in thymic and lymphocyte cell nuclei, modulating expression of genes involved in T cell maturation, cytokine production, and broader immune regulation.
Proposed effects include support for thymic function — particularly relevant given the well-documented age-related thymic involution that contributes to immunosenescence in older adults — alongside modulation of lymphocyte chromatin organisation and immune cell maturation pathways. Russian research has reported crystagen-induced improvements in lymphocyte counts, T helper cell function, and clinical recovery from infections in elderly populations and in patients recovering from immunosuppressive treatments. The peptide is often used alongside thymalin (a related thymic peptide preparation also in this database) as part of broader Khavinson immune-support protocols.
As with the rest of the Khavinson family, the efficacy evidence base sits within Russian gerontology and immunology research with limited independent Western validation. Crystagen is not validated as a treatment for primary immunodeficiency, HIV-related immune dysfunction, or other formally diagnosed immune conditions, and should not displace evidence-based immune therapy. The brief plasma half-life (around 30 minutes) reflects the proposed model of transient signalling triggering longer-lasting transcriptional changes in immune cell populations.
Livagen
Livagen is a short tripeptide (Lys-Glu-Asp) within the Khavinson bioregulator family — peptides hypothesised to regulate gene expression in tissue-specific ways by binding to gene promoter regions. Livagen is positioned as the liver-targeted member of this family, intended to modulate hepatocyte gene expression in ways that support liver regeneration and counteract age-related decline in hepatic function.
Proposed mechanisms include modulation of chromatin condensation states in hepatocyte and lymphocyte nuclei, upregulation of genes involved in hepatic detoxification pathways (cytochrome P450 enzymes, glutathione synthesis), and immunomodulatory effects in liver-resident immune cells. Russian research has reported livagen-induced increases in hepatocyte regeneration markers in animal models of liver injury and changes in lymphocyte chromatin organisation consistent with cellular rejuvenation.
As with all Khavinson tripeptides, the proposed action model is that livagen acts as a transient signalling molecule triggering longer-lasting changes in gene expression. Plasma exposure is brief (around 30 minutes) but downstream transcriptional effects are claimed to persist for weeks, justifying pulse-dosing protocols of 10-30 day courses repeated periodically. The evidence base for clinical efficacy is dominated by Russian gerontology research with limited independent Western replication, and clinical use outside Russia remains largely anecdotal. Livagen should not be used as a substitute for evidence-based liver disease management.
Risks & Safety
Crystagen
Common
generally reported as well tolerated.
Serious
very limited Western clinical data; theoretical concern with use in autoimmune disease (immune-modulating peptides may unpredictably affect autoimmune activity).
Rare
allergic reactions. Should not replace evidence-based immune therapy in serious immunodeficiency.
Livagen
Common
generally reported as well tolerated.
Serious
very limited Western clinical data; long-term safety in the context of pre-existing liver disease is not established.
Rare
allergic reactions. Like other Khavinson bioregulators, the evidence base is significantly thinner than the marketing suggests.
Full Profiles
Crystagen →
A Khavinson tripeptide (Glu-Asp-Pro) developed in Russia as a tissue-specific bioregulator targeting the thymus and broader immune system. Promoted for age-related immune decline (immunosenescence), recovery from immunosuppressive treatments, and as a general immune support during the cold and flu season. Within the same Khavinson family as thymalin and thymosin alpha-1, both already in your database.
Livagen →
A Khavinson tripeptide (Lys-Glu-Asp) developed in Russia as a tissue-specific bioregulator targeting the liver. Promoted for supporting liver regeneration, age-related liver decline, and as part of broader anti-ageing protocols. Sits in the same family as epithalon (pineal), cortagen (brain), and pinealon (pineal/brain). Most evidence is from Russian preclinical work — rigorous Western clinical trials are essentially nonexistent.